High serum IL-17A is associated with bone destruction in newly diagnosed multiple myeloma patients

High serum IL-17A is associated with bone destruction in newly diagnosed multiple myeloma patients

BackgroundMultiple myeloma (MM) is a malignant proliferative disease of the blood system, characterized by the abnormal growth of clonal plasma cells in the bone marrow. The bone marrow microenvironment (BMM) is highly critical in the pathological process of MM. Many studies have shown that serum in...

Full description

Bibliographic Details
Main Authors:	Mengmeng Dong, Jinna Zhang, Qingxiao Chen, Donghua He, Haimeng Yan, Gaofeng Zheng, Xiaoyan Han, Jingsong He, Zhen Cai
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Series:	Frontiers in Oncology
Subjects:	IL-17A multiple myeloma bone destruction best overall therapeutic effect pfs os
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.936670/full

Similar Items

Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
by: JingSong He, et al.
Published: (2021-07-01)

Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017
by: Xuejiao Yin, et al.
Published: (2018-04-01)

Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years
by: Si Yu Lin, et al.
Published: (2024-07-01)

Construction and validation of an 18F-FDG-PET/CT-based prognostic model to predict progression-free survival in newly diagnosed multiple myeloma patients
by: Xiaoqing Dong, et al.
Published: (2024-12-01)

The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patients
by: Linlin Huang, et al.
Published: (2024-12-01)

Myeloma-derived IL-32γ induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axis
by: Yang Liu, et al.
Published: (2022-12-01)

Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study
by: Haimin Chen, et al.
Published: (2023-12-01)

The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China
by: Qingxiao Chen, et al.
Published: (2022-12-01)

Antibiotics Modulate Chemotherapy Efficacy in Patients with Esophageal Cancer
by: Wu C, et al.
Published: (2020-06-01)

Negative impact of antibiotic administration on the clinical activity in patients with advanced gastric cancer
by: Xiaoyun Zhang, et al.
Published: (2021-01-01)

Prognostic predictors of adrenocortical carcinoma: A single-center thirty-year experience
by: Li-Hsin Pan, et al.
Published: (2023-03-01)

Efficacy and safety of metformin in combination with chemotherapy in cancer patients without diabetes: systematic review and meta-analysis
by: Kang Yang, et al.
Published: (2023-07-01)

Surgery Versus Perioperative Chemotherapy In Non Metastatic Muscle Invasive Bladder Carcinoma
by: Sarah Ali, et al.
Published: (2022-01-01)

Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
by: Xiaoyan Han, et al.
Published: (2021-06-01)

Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients
by: Mengmeng Dong, et al.
Published: (2022-06-01)

Corrigendum: Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
by: Xiaoyan Han, et al.
Published: (2021-09-01)

Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China
by: Xiaoyan Han, et al.
Published: (2024-05-01)

Screening to Identify an Immune Landscape-Based Prognostic Predictor and Therapeutic Target for Prostate Cancer
by: Yanting Shen, et al.
Published: (2021-11-01)

Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients
by: Shuai Jiang, et al.
Published: (2022-02-01)

Real world results of locally advanced and metastatic lung cancer patients treated with platinum doublet chemotherapy in first line: Moroccan cohort
by: Hassan Abdelilah Tafenzi, et al.
Published: (2024-09-01)

Immunotherapy in patients with metastatic castration-resistant prostate cancer: a meta-analysis of data from 7 phase III studies and 3 phase II studies
by: Anqiang Zhang, et al.
Published: (2022-09-01)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
by: Jingsong He, et al.
Published: (2020-12-01)

Long-term outcomes of induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
by: Xiaoyan Zhao, et al.
Published: (2024-11-01)

Outcome predictors in a series of 40 patients after surgery for low-grade gliomas
by: M. Dobran, et al.
Published: (2024-06-01)

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway
by: Li Yang, et al.
Published: (2018-02-01)

Karnofsky Performance Status (KPS) ≤60 Is Strongly Associated With Shorter Brain-Specific Progression-Free Survival Among Patients With Metastatic Breast Cancer With Brain Metastases
by: Mark Freeman, et al.
Published: (2022-07-01)

Protein expression of CD44 in patients with meningioma tumors: association with clinicopathological parameters and survival
by: Trupti Trivedi, et al.
Published: (2024-12-01)

RETRACTED: The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis
by: Fangcheng Shen, et al.
Published: (2023-02-01)

Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study
by: Narendranath Epperla, et al.
Published: (2023-11-01)

Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis
by: Yanhui Li
Published: (2023-12-01)

Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors
by: Giandomenico Roviello, et al.
Published: (2022-08-01)

Risk Factors for Early Hydrocephalus on Post Unilateral Thalamic Tumor Resection
by: Linpeng Zhang, et al.
Published: (2022-04-01)

Prognostic Stratification of Metastatic Prostate Cancer Patients Treated With Abiraterone and Enzalutamide Through an Integrated Analysis of Circulating Free microRNAs and Clinical Parameters
by: Evgeniya Sharova, et al.
Published: (2021-03-01)

Sunitinib versus imatinib dose escalation after failure of imatinib standard dose in patients with advanced Gastrointestinal stromal tumors – a real-world multi-center study
by: Shaoqing Huang, et al.
Published: (2023-04-01)

Prognostic value of pan-immune-inflammation value in colorectal cancer patients: A systematic review and meta-analysis
by: Xiao-Chuan Yang, et al.
Published: (2022-12-01)

Prognostic impact of the controlling nutritional status score in patients with hematologic malignancies: A systematic review and meta-analysis
by: Chuanyang Lu, et al.
Published: (2022-10-01)

Efficacy of Intermittent, Oral Famciclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in Multiple Myeloma Patients
by: Gaofeng Zheng, et al.
Published: (2022-03-01)

The advanced lung cancer inflammation index predicts chemotherapy response and infection risk in multiple myeloma patients receiving induction chemotherapy
by: Jie Cheng, et al.
Published: (2022-11-01)

The prognostic role of an optimal machine learning model based on clinical available indicators in HCC patients
by: Xiaoying Lou, et al.
Published: (2024-07-01)

Clinical Characteristics of 18 Patients with Psoriasis and Multiple Myeloma Identified Through Digital Health Crowdsourcing
by: Joy Q. Jin, et al.
Published: (2020-07-01)